What are the recommended dosing, monitoring, and safety considerations for using acalabrutinib in patients with chronic lymphocytic leukemia?

Acalabrutinib for CLL: Dosing, Monitoring, and Safety

Acalabrutinib is dosed at 100 mg orally twice daily (approximately every 12 hours) continuously until disease progression, and is a Category 1 preferred regimen for both treatment-naïve and relapsed/refractory CLL regardless of age, comorbidities, or high-risk features including del(17p)/TP53 mutations. 1, 2

Dosing and Administration

• Standard dose: 100 mg orally every 12 hours
• Administration: Swallow tablets whole with water; may take with or without food. Do NOT chew, crush, dissolve, or cut tablets 2
• Duration: Continue until disease progression or unacceptable toxicity 1, 2
• Dose modifications:
  • Hold 3 days before/after minor surgery, 7 days before/after major surgery 3
  • With moderate CYP3A inhibitors: reduce dose 2
  • Avoid strong CYP3A inhibitors and inducers 2
  • Avoid in severe hepatic impairment 2

Clinical Efficacy Context

The ASCEND trial established acalabrutinib's superiority in relapsed/refractory CLL with 81% ORR, median PFS not reached at 16 months, and 1-year PFS of 88% versus 68-69% for idelalisib/rituximab or bendamustine/rituximab 1. Responses are consistent across high-risk subgroups including del(11q), unmutated IGHV, del(17p), and TP53 mutations 1. In treatment-naïve patients, acalabrutinib ± obinutuzumab demonstrates similar efficacy 1.

Critical limitation: Acalabrutinib is NOT effective for ibrutinib-refractory CLL with BTK C481S mutations 1. However, 76% of patients intolerant to ibrutinib respond to acalabrutinib, with 72% of prior ibrutinib-related adverse events not recurring 1, 4.

Monitoring Requirements

Baseline Assessment

• Complete blood count with differential
• Hepatic function tests (ALT, AST, bilirubin)
• Cardiac assessment if cardiovascular comorbidities present 5
• TP53 status (del17p and/or TP53 mutations) 5
• IGHV mutation status 5
• Medication review for CYP3A interactions 2

Ongoing Monitoring

• Hematologic: Monitor CBC regularly for cytopenias 2

  • Grade ≥3 neutropenia occurs in 12-19% 1
  • Grade ≥3 thrombocytopenia in 9% 1
  • Grade ≥3 anemia in 15% 1

• Hepatic: Monitor liver function throughout treatment for hepatotoxicity including drug-induced liver injury 2

• Cardiovascular: Monitor for arrhythmias (particularly atrial fibrillation) and hypertension 2

• Infectious: Monitor for signs/symptoms of infection 2

Safety Profile and Management

Most Common Adverse Events (Any Grade)

The toxicity profile is generally favorable with predominantly mild-to-moderate events 1:

• Headache (22-39%)
• Diarrhea (18-58%)
• Neutropenia (19%)
• Cough (15-33%)
• Anemia (15%)
• Upper respiratory tract infection
• Fatigue (10-18%)
• Nausea (7-27%)

Serious Adverse Events Requiring Specific Management

1. Cardiac Arrhythmias

• Atrial fibrillation occurs in approximately 7% (much lower than ibrutinib's 9%) 3, 2
• Monitor for symptoms; manage with rate/rhythm control
• Consider non-warfarin anticoagulation if needed
• Discontinue only if uncontrollable 2

2. Hemorrhage

• Major bleeding in 5% 6
• Avoid concurrent warfarin (use alternative anticoagulants) 3, 2
• Hold acalabrutinib perioperatively as noted above
• Monitor patients on antiplatelet/anticoagulant therapy closely 2

3. Infections

• Serious/opportunistic infections can occur 2
• Pneumonia is most common serious infection (11%) 6
• Consider prophylaxis in high-risk patients:
  • HSV/VZV prophylaxis for those with recurrent reactivations or on concurrent steroids 7
  • PCP prophylaxis per institutional guidelines
  • Monitor for CMV per institutional protocols 3

4. Hypertension

• Occurs in 7% (Grade ≥3) 6
• Manage with antihypertensives
• Discontinue only if uncontrollable 2

5. Second Primary Malignancies

• Skin cancers and other solid tumors reported 2
• Advise sun protection measures 2

6. Hepatotoxicity

• Drug-induced liver injury can occur 2
• Interrupt treatment if ALT/AST >5× ULN
• May resume at reduced dose when resolved 2

Expected Lymphocytosis

• Transient increase in absolute lymphocyte count occurs in most patients during first few weeks 1
• This does NOT signify disease progression
• May persist for several weeks on treatment
• Do not discontinue therapy for isolated lymphocytosis

Dose Modifications for Toxicity

Grade 3 or higher non-hematologic toxicity OR Grade 3 or higher neutropenia with infection OR Grade 4 hematologic toxicity:

1. Interrupt acalabrutinib
2. Once toxicity resolves to Grade 1 or baseline:
   • First occurrence: Resume at 100 mg twice daily
   • Second occurrence: Resume at 100 mg once daily
   • Third occurrence: Discontinue 2

Drug Interactions - Critical

Avoid completely:

• Strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir)
• Strong CYP3A inducers (rifampin, phenytoin, carbamazepine, St. John's Wort)
• Warfarin 3, 2

Moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem):

• Reduce acalabrutinib to 100 mg once daily 2

If strong CYP3A inducer unavoidable:

• Increase acalabrutinib dose per prescribing information 2

Special Populations

• Elderly/frail patients: No dose adjustment needed; efficacy maintained regardless of age 1
• Cardiovascular comorbidities: Lower cardiac toxicity than ibrutinib makes acalabrutinib preferred choice 8, 5
• Severe hepatic impairment: Avoid acalabrutinib 2
• Pregnancy: May cause fetal harm and dystocia; avoid 2
• Lactation: Advise not to breastfeed 2

Transitioning Therapy

At progression:

• Transition to next therapy as soon as possible after stopping acalabrutinib
• Disease progression may accelerate when BTK inhibitor stopped
• Minimize treatment-free interval 3

Common pitfall: Do not assume all BTK inhibitor resistance is the same. Check for BTK C481S mutation at relapse, as this confers cross-resistance to acalabrutinib 1, 6. Consider venetoclax-based regimens for BTK-resistant disease 8, 5.